Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects (Q36569766)

15 August 2017

1 reference

title

Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects (English)

1 reference

15 August 2017

1

Andreas Pfützner

1 reference

15 August 2017

Christian A Schneider

series ordinal

2

1 reference

PubMed ID

16918264

15 August 2017

Thomas Forst

series ordinal

3

1 reference

15 August 2017

1 July 2006

1 reference

Expert Review of Cardiovascular Therapy

15 August 2017

1 reference

15 August 2017

4

1 reference

15 August 2017

4

1 reference

15 August 2017

445-459

1 reference

Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections

15 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Trends in the leading causes of death in the United States, 1970-2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Pathogenesis of non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Vasoprotection by nitric oxide: mechanisms and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Molecular and physiologic actions of insulin related to production of nitric oxide in vascular endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Atherosclerosis — An Inflammatory Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Thiazolidinediones: a review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Cardiovascular risk factors associated with insulin resistance: effects of oral antidiabetic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Thiazolidinediones and blood lipids in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

21 January 2018

Rosiglitazone/Metformin

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Roles of PPARs in health and disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Thiazolidinediones: an update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

The pleiotropic functions of peroxisome proliferator-activated receptor gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

PPARgamma, the ultimate thrifty gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide-based regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Pioglitazone as monotherapy or in combination with sulfonylurea or metformin enhances insulin sensitivity (HOMA-S or QUICKI) in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Pioneer study: PPARgamma activation results in overall improvement of clinical and metabolic markers associated with insulin resistance independent of long-term glucose control

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Improved glycemic control and lipid profile in a randomized study of pioglitazone compared with acarbose in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, para

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Metabolic and additional vascular effects of thiazolidinediones.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Influence of glucose control and improvement of insulin resistance on microvascular blood flow and endothelial function in patients with diabetes mellitus type 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Troglitazone, an antidiabetic drug, improves left ventricular mass and diastolic function in normotensive diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Pioglitazone improves left ventricular diastolic function in patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Pharmacological PPARgamma stimulation in contrast to beta cell stimulation results in an improvement in adiponectin and proinsulin intact levels and reduces intima media thickness in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Pioglitazone-induced insulin sensitization improves vascular endothelial function in nondiabetic patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Pioglitazone protects against thrombosis in a mouse model of obesity and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

The effects of PPAR-gamma ligand pioglitazone on platelet aggregation and arterial thrombus formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Peroxisome proliferator-activated receptor gamma ligands inhibit Rho/Rho kinase pathway by inducing protein tyrosine phosphatase SHP-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Cardiovascular effects of rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Pioglitazone: a review of its use in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Thiazolidinedione-induced edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Changes in liver tests during 1-year treatment of patients with Type 2 diabetes with pioglitazone, metformin or gliclazide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Fatal liver failure associated with pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Pioglitazone-induced hepatic injury in a patient previously receiving troglitazone with success

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Second-generation thiazolidinediones and hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Pioglitazone initiation and subsequent hospitalization for congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Prevention Conference VI: Diabetes and Cardiovascular disease: Writing Group I: epidemiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Central role of the adipocyte in the insulin-sensitising and cardiovascular risk modifying actions of the thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

The PROactive study: some answers, many questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.4.4.445

21 January 2018

Identifiers

DOI

10.1586/14779072.4.4.445

1 reference

15 August 2017

1 reference

PubMed ID

16918264